Health Care & Life Sciences » Pharmaceuticals | Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Cash & Short Term Investments
68,157.00
196,367.00
111,750.00
82,387.00
136,986.00
Total Accounts Receivable
-
-
-
-
6,491.00
Inventories
-
-
-
5,640.00
17,214.00
Other Current Assets
118.00
236.00
205.00
389.00
4,469.00
Total Current Assets
68,275.00
196,603.00
111,955.00
88,416.00
165,160.00
Net Property, Plant & Equipment
589.00
642.00
531.00
593.00
1,134.00
Other Assets
3,694.00
16,099.00
3,443.00
843.00
312.00
Total Assets
72,558.00
213,344.00
115,929.00
89,852.00
166,606.00
Accounts Payable
13,542.00
-
-
-
23,256.00
Other Current Liabilities
2,134.00
18,331.00
19,579.00
29,430.00
14,891.00
Total Current Liabilities
15,676.00
18,331.00
19,579.00
29,430.00
38,147.00
Long-Term Debt
-
200,000.00
151,241.00
22,665.00
115,962.00
Other Liabilities
1,534.00
172.00
322.00
216.00
18,015.00
Total Liabilities
17,210.00
218,503.00
171,142.00
52,311.00
172,124.00
Common Equity (Total)
55,348.00
5,159.00
55,213.00
37,541.00
5,518.00
Total Shareholders' Equity
55,348.00
5,159.00
55,213.00
37,541.00
5,518.00
Total Equity
55,348.00
5,159.00
55,213.00
37,541.00
5,518.00
Liabilities & Shareholders' Equity
72,558.00
213,344.00
115,929.00
89,852.00
166,606.00

About Synergy Pharmaceuticals

View Profile
Address
420 Lexington Avenue
New York New York 10170
United States
Employees -
Website http://www.synergypharma.com
Updated 09/14/2018
Synergy Pharmaceuticals, Inc. engages on the development and commercialization of novel gastrointestinal therapies. Its commercial product, plecanatide, is marketed under the trademark name TRULANCE, which seeks to treat adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. The company was founded by Kunwar Shailubhai on November 15, 2005 and is headquartered in New York, NY.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.